These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 32205101)

  • 1. Comments on the 2019 ESC/EAS guidelines for the management of dyslipidemias.
    ; ; ;
    Rev Esp Cardiol (Engl Ed); 2020 May; 73(5):348-353. PubMed ID: 32205101
    [No Abstract]   [Full Text] [Related]  

  • 2. A clinical perspective on the 2019 ESC/EAS guidelines for the management of dyslipidaemias: PCSK-9 inhibitors for all?
    Dykun I; Mahabadi AA; Rassaf T
    Eur Heart J; 2020 Jun; 41(24):2331. PubMed ID: 32031601
    [No Abstract]   [Full Text] [Related]  

  • 3. Do we need a redefinition of the cardiovascular risk categories used in the 2019 ESC/EAS guidelines on dyslipidaemias?
    Gragnano F; Calabrò P
    Eur Heart J; 2020 Jun; 41(24):2332. PubMed ID: 32031600
    [No Abstract]   [Full Text] [Related]  

  • 4. News from ESC congress 2019: New ESC/EAS guidelines for dyslipidaemia management published.
    Stock J
    Atherosclerosis; 2019 Dec; 291():124-126. PubMed ID: 31668350
    [No Abstract]   [Full Text] [Related]  

  • 5. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.
    Mach F; Baigent C; Catapano AL; Koskinas KC; Casula M; Badimon L; Chapman MJ; De Backer GG; Delgado V; Ference BA; Graham IM; Halliday A; Landmesser U; Mihaylova B; Pedersen TR; Riccardi G; Richter DJ; Sabatine MS; Taskinen MR; Tokgozoglu L; Wiklund O;
    Eur Heart J; 2020 Jan; 41(1):111-188. PubMed ID: 31504418
    [No Abstract]   [Full Text] [Related]  

  • 6. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.
    ; ;
    Atherosclerosis; 2019 Nov; 290():140-205. PubMed ID: 31591002
    [No Abstract]   [Full Text] [Related]  

  • 7. [ESC/EAS Guidelines for the management of dyslipidaemias].
    Reiner Ž; Catapano AL; De Backer G; Graham I; Taskinen MR; Wiklund O; Agewall S; Alegría E; Chapman MJ; Durrington P; Erdine S; Halcox J; Hobbs RH; Kjekshus JK; Perrone Filardi P; Riccardi G; Storey RF; David W;
    Rev Esp Cardiol; 2011 Dec; 64(12):1168.e1-1168.e60. PubMed ID: 22115524
    [No Abstract]   [Full Text] [Related]  

  • 8. How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic.
    Barkas F; Milionis H; Kostapanos MS; Mikhailidis DP; Elisaf M; Liberopoulos E
    Curr Med Res Opin; 2015 Feb; 31(2):221-8. PubMed ID: 25418708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [2016 ESC/EAS Guidelines for the Management of Dyslipidaemias].
    Catapano AL; Graham I; De Backer G; Wiklund O; Chapman MJ; Drexel H; Hoes AW; Jennings CS; Landmesser U; Pedersen TR; Reiner Ž; Riccardi G; Taskinen MR; Tokgozoglu L; Verschuren WM; Vlachopoulos C; Wood DA; Zamorano JL
    Kardiol Pol; 2016; 74(11):1234-1318. PubMed ID: 27910077
    [No Abstract]   [Full Text] [Related]  

  • 10. Comments on the 2016 ESC/EAS Guidelines for the Management of Dyslipidemias.
    Pérez de Isla L; ; Pérez de Isla L; Fernández PLS; Álvarez-Sala Walther L; Barrios Alonso V; Castro Conde A; Galve Basilio E; García Ortiz L; Mata López P; ; Alegría Ezquerra E; Cordero Fort A; Cosin Sales J; Escobar Cervantes C; García-Moll Marimón X; José Gómez Doblas J; Marzal Martín D; Murga Eizagaechevarria N; de Pablo Zarzosa C; Miguel Rincón L; Sanchis Forés J; ; Alberto San Román Calvar J; Alfonso Manterola F; Arribas Ynsaurriaga F; Evangelista Masip A; Ferreira González I; Jiménez Navarro M; Marín Ortuño F; Pérez de Isla L; Rodríguez Padial L; Luis Sánchez Fernández P; Sionis Green A; Vázquez García R
    Rev Esp Cardiol (Engl Ed); 2017 Feb; 70(2):72-77. PubMed ID: 28131410
    [No Abstract]   [Full Text] [Related]  

  • 11. Prevention guidelines and EAS/ESC guidelines for the treatment of dyslipidaemias: A look to the future.
    Catapano AL; Ray KK; Tokgözoglu L
    Atherosclerosis; 2022 Jan; 340():51-52. PubMed ID: 34863532
    [No Abstract]   [Full Text] [Related]  

  • 12. New ESC/EAS Guidelines for the management of dyslipidaemias - any controversies behind the consensus?
    Reiner Z
    Eur J Cardiovasc Prev Rehabil; 2011 Oct; 18(5):724-7. PubMed ID: 21945917
    [No Abstract]   [Full Text] [Related]  

  • 13. The changing landscape of lipid-lowering therapy after the new ESC/EAS guidelines for the management of dyslipidaemias: Launching the era of triple hypolipidaemic therapy in very high risk patients.
    Rallidis LS
    Atherosclerosis; 2020 Jan; 292():231-233. PubMed ID: 31784033
    [No Abstract]   [Full Text] [Related]  

  • 14. [The new 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk: comparison with the ESC/EAS recommendations for the management of dyslipidemias].
    Catapano AL; Averna M; Faggiano P; Novo S
    G Ital Cardiol (Rome); 2014 Jan; 15(1):19-20. PubMed ID: 24503730
    [No Abstract]   [Full Text] [Related]  

  • 15. CAC Score Improves Coronary and CV Risk Assessment Above Statin Indication by ESC and AHA/ACC Primary Prevention Guidelines.
    Mahabadi AA; Möhlenkamp S; Lehmann N; Kälsch H; Dykun I; Pundt N; Moebus S; Jöckel KH; Erbel R;
    JACC Cardiovasc Imaging; 2017 Feb; 10(2):143-153. PubMed ID: 27665163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New european guidelines for dyslipidemia].
    Riesen WF; Virgini V; Vogt B; Rodondi N
    Rev Med Suisse; 2012 Mar; 8(331):525-6, 528-30. PubMed ID: 22471115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Updated treatment thresholds in the 2019 ESC/EAS dyslipidaemia guidelines substantially expand indications for statin use for primary prevention at population level: Results from the Rotterdam Study.
    Pavlović J; Kavousi M; Ikram MA; Leening MJG
    Atherosclerosis; 2020 Apr; 299():64-66. PubMed ID: 32169303
    [No Abstract]   [Full Text] [Related]  

  • 18. [A perspective to lipid lowering therapy after ESC/EAS guidelines for the management of dyslipidaemias and the European guidelines on cardiovascular disease prevention in clinical practice].
    Ural D
    Turk Kardiyol Dern Ars; 2012 Jun; 40(4):293-7. PubMed ID: 22951844
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of four international cardiovascular disease prediction models and the prevalence of eligibility for lipid lowering therapy in HIV infected patients on antiretroviral therapy.
    Begovac J; Dragović G; Višković K; Kušić J; Perović Mihanović M; Lukas D; Jevtović Đ
    Croat Med J; 2015 Feb; 56(1):14-23. PubMed ID: 25727038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.
    Catapano AL; Graham I; De Backer G; Wiklund O; Chapman MJ; Drexel H; Hoes AW; Jennings CS; Landmesser U; Pedersen TR; Reiner Ž; Riccardi G; Taskinen MR; Tokgozoglu L; Verschuren WMM; Vlachopoulos C; Wood DA; Zamorano JL; Cooney MT;
    Eur Heart J; 2016 Oct; 37(39):2999-3058. PubMed ID: 27567407
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.